Transcription factor MYB1R1 Antibody

What is the MYBL1 transcription factor and why is it significant in cancer research?

MYBL1 is a strong transcriptional activator belonging to the MYB family of proteins that plays important roles in cancer progression. MYBL1 contains a highly conserved helix-turn-helix DNA-binding domain at the N-terminus with three tandem repeated domains (R1, R2, and R3), a trans-activating domain (TAD) in the central portion, and a C-terminal negative regulatory domain (NRD) . It recognizes and binds to a specific DNA consensus sequence [PyAAC(G/T)G], known as the MYB-binding site (MBS), to regulate gene expression .

Research significance is demonstrated by its overexpression in triple-negative breast cancers (TNBCs) and its emerging role in coordinated activity with other chromosome 8q genes (VCPIP1, MYC, and BOP1) in TNBC pathogenesis . When working with MYBL1 antibodies, researchers should consider that multiple reference sequence variants and protein isoforms exist, which can affect antibody binding specificity and experimental outcomes .

How do MYBL1 antibodies help distinguish between MYB family members?

Methodologically, researchers must select antibodies raised against unique epitopes within MYBL1 that don't cross-react with other MYB family proteins (MYB and MYBL2). While all MYB family members share highly conserved DNA-binding domains, MYBL1 contains specific structural features including a heptad leucine-zipper repeat that is only present in MYB and MYBL1 but not in MYBL2 .

When validating antibody specificity:

• Perform Western blots using recombinant proteins for all three MYB family members

• Use positive and negative control cell lines with known MYBL1 expression profiles

• Verify results using genetic approaches (siRNA knockdown or CRISPR knockout)

• Consider epitope location relative to known protein domains

Antibodies directed against the less conserved C-terminal regions typically offer better specificity than those targeting the highly conserved N-terminal DNA-binding domains.

What types of MYBL1 transcript variants and protein isoforms should researchers consider when using antibodies?

Current research has identified multiple MYBL1 transcripts and protein isoforms that researchers must consider when selecting antibodies. According to recent analyses, there are 17 sequences designated as NCBI Reference Sequences (RefSeqs) corresponding to the MYBL1 gene, with 10 being unique based on sequence alignment .

When selecting antibodies for specific research questions:

• Determine which protein domains are present in the isoforms of interest

• Consider whether antibodies recognize all or specific isoforms

• Validate antibody binding to different isoforms using recombinant protein standards

• Design experiments that account for potential isoform-specific functions

This consideration is particularly important as MYBL1 exhibits tissue-specific expression patterns and potentially different functional roles for different isoforms.

What are the optimal protocols for using MYBL1 antibodies in triple-negative breast cancer research?

For TNBC research with MYBL1 antibodies, researchers should implement multi-level validation approaches:

Western Blot Protocol:

• Include multiple TNBC cell lines (e.g., MDA-MB-231, BT-549, Hs 578T) alongside non-tumor controls (e.g., MCF10A)

• Use appropriate protein extraction methods that preserve nuclear proteins

• Load 25-50μg of total protein per lane

• Include positive controls with known MYBL1 expression

• Perform densitometric analysis to quantify expression differences

Immunohistochemistry Protocol:

• Optimize antigen retrieval methods for FFPE tissue sections

• Include adjacent normal tissue as internal control

• Use multiple MYBL1 antibodies targeting different epitopes when possible

• Score intensity and percentage of positive cells systematically

• Correlate with transcript expression data when available

Validation Strategy:
Compare protein expression results with mRNA expression data as demonstrated in recent studies where MYBL1 protein levels generally corresponded with transcript levels in TNBC cell lines, although some exceptions were observed .

How should researchers design experiments to investigate MYBL1's role in transcriptional regulation?

To effectively study MYBL1's role as a transcription factor:

ChIP Protocol Design:

• Cross-link protein-DNA complexes with formaldehyde (typically 1% for 10 minutes)

• Sonicate chromatin to 200-500bp fragments

• Immunoprecipitate using validated MYBL1 antibodies

• Include IgG controls and input samples

• Verify enrichment at known targets (e.g., MYC) by qPCR before sequencing

Target Gene Analysis:

• Identify potential MYBL1 binding sites by screening for the consensus sequence [PyAAC(G/T)G]

• Verify binding by ChIP-qPCR

• Validate functional relevance through expression analysis after MYBL1 knockdown/overexpression

• Consider co-immunoprecipitation studies to identify protein partners (e.g., C/EBP family members)

Functional Analysis:
Combine MYBL1 antibody data with gene expression analysis following MYBL1 knockdown, as demonstrated in studies where MYBL1 knockdown affected expression of multiple genes located on chromosomal regions 8q13.1–8q24.3, including VCPIP1, MYC, and BOP1 .

What controls should be included when using MYBL1 antibodies in protein expression studies?

Proper controls are essential for reliable MYBL1 antibody experiments:

Essential Controls:

• Positive controls: Cell lines with confirmed high MYBL1 expression (e.g., MDA-MB-231, BT-549 for TNBC studies)

• Negative controls: Cell lines with low/no MYBL1 expression (e.g., MCF10A as non-tumor control)

• Knockdown/knockout validation: siRNA or CRISPR-mediated reduction of MYBL1 to confirm antibody specificity

• Loading controls: Appropriate housekeeping proteins for the cellular compartment being studied

• Isotype controls: For immunoprecipitation and ChIP experiments

Methodological Considerations:

• Include concentration-matched isotype control antibodies in immunoprecipitation experiments

• For subcellular localization studies, include markers for nuclear (e.g., lamin) and cytoplasmic (e.g., GAPDH) fractions

• When studying multiple MYB family members, include controls to verify antibody specificity for each protein

How can MYBL1 antibodies be used to study protein-protein interactions in cancer research?

To investigate MYBL1 protein interactions:

Co-Immunoprecipitation Protocol:

• Prepare nuclear extracts from cells of interest

• Immunoprecipitate with MYBL1 antibody

• Analyze co-precipitated proteins by mass spectrometry or Western blot

• Validate interactions using reverse co-IP

• Confirm functional relevance through mutation of interaction domains

Known Interactors to Investigate:
MYBL1 has been shown to interact with transcription factors and co-activators including:

• CAAT enhancer-binding protein (C/EBP) family members

• CBP/p300 histone acetyltransferase

• Members of the ETS family

• GATA1 transcription factor

Proximity Ligation Assay (PLA):
For detecting protein interactions in situ, researchers can use PLA with:

• Primary antibodies against MYBL1 and suspected interacting partner

• Species-specific PLA probes

• Amplification and detection reagents

• Confocal microscopy for visualization

This approach is particularly valuable for confirming interactions in patient samples where co-IP may not be feasible.

What approaches help distinguish between transcriptional activities of different MYB family members?

To differentiate the specific roles of MYBL1 from other MYB family members:

Sequential ChIP (Re-ChIP):

• Perform initial ChIP with MYBL1-specific antibody

• Elute protein-DNA complexes

• Perform second ChIP with antibodies against other MYB family members

• Quantify overlap and distinct targets

DNA-binding Specificity Analysis:
While all MYB family members recognize the same core DNA consensus sequence [PyAAC(G/T)G] , subtle differences in binding preferences can be detected through:

• Electrophoretic mobility shift assays with competing antibodies

• DNA pull-down assays followed by Western blotting

• Comparing ChIP-seq datasets for different MYB family members

Transcriptional Reporter Assays:

• Construct reporters containing known or putative MYBL1 binding sites

• Test activation by different MYB family members

• Use antibodies in supershift assays to confirm specificity

How can researchers use MYBL1 antibodies to investigate its role in cancer progression?

For studying MYBL1's role in cancer:

Tissue Microarray Analysis:

• Stain TMAs containing normal, pre-malignant, and malignant tissues

• Score nuclear and cytoplasmic MYBL1 staining separately

• Correlate with clinical parameters and outcome data

• Compare with other markers on chromosome 8q (VCPIP1, MYC, BOP1)

Patient Sample Analysis Strategy:
Recent studies have developed computer scripts to detect various MYBL1 alterations in patient samples, including:

• Gene expression levels

• Amplifications

• Homozygous and heterozygous deletions

• Protein expression differences

• Gene fusions

This approach revealed that alterations in MYBL1, VCPIP1, MYC, and BOP1 genes occur concurrently in many TNBC patients, suggesting coordinated activity .

How should researchers address discrepancies between MYBL1 protein and mRNA expression levels?

When facing inconsistencies between protein and transcript data:

Methodological Approaches:

• Verify antibody specificity using multiple antibodies targeting different epitopes

• Consider post-transcriptional regulation mechanisms:

  • microRNA regulation

  • RNA stability differences

  • Translational efficiency

• Assess protein stability and turnover rates using cycloheximide chase experiments

• Investigate post-translational modifications that might affect antibody binding

Case Example:
In TNBC cell line studies, while most cell lines showed correlation between MYBL1 transcript and protein levels, Hs 578T cells demonstrated lower levels of VCPIP1 protein expression despite comparable mRNA levels . This highlights the importance of validating findings at both RNA and protein levels.

What are common pitfalls in MYBL1 antibody-based research and how can they be addressed?

Common challenges and solutions:

Specificity Issues:

• Cross-reactivity with other MYB family members due to conserved domains

• Solution: Use epitopes from less conserved regions and validate with knockdown approaches

Isoform Detection:

• Inconsistent detection of different protein isoforms

• Solution: Determine which isoforms are recognized by specific antibodies and validate with recombinant proteins

Subcellular Localization:

• Inefficient extraction of nuclear proteins

• Solution: Use appropriate nuclear extraction protocols with phosphatase inhibitors

Fixation-Dependent Epitope Masking:

• Some epitopes may be masked by certain fixation methods

• Solution: Compare multiple fixation methods and antigen retrieval techniques

How can researchers integrate MYBL1 antibody data with genomic alterations in cancer studies?

For integrative analysis:

Multi-Omics Integration Approach:

• Combine protein expression data (IHC/Western blot) with:

  • Copy number data (MYBL1 is frequently amplified in chromosome 8q alterations)

  • Gene expression profiles

  • Mutation data

  • Clinical parameters

Data Integration Framework:

Analysis Strategy:

• Identify patients with MYBL1 alterations using computer scripts as demonstrated in recent studies

• Group alterations by type (expression changes, amplifications, deletions, fusions)

• Correlate alterations with co-occurring changes in other genes (VCPIP1, MYC, BOP1)

• Perform survival analysis based on MYBL1 status

This integrative approach has revealed that MYBL1 gene alterations often co-occur with alterations in VCPIP1, MYC, and BOP1 genes in TNBC patients, suggesting coordinated activity of these chromosome 8q genes in cancer progression .